Drug Profile
LBVE 013
Alternative Names: LBVE; LBVE013; Multivalent pneumococcal conjugate vaccine; Pneumococcal-13 valent conjugate vaccine - LG Life SciencesLatest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pneumococcal infections
Most Recent Events
- 25 Jul 2022 Discontinued - Phase-II for Pneumococcal infections (In infants, Prevention) in South Korea (IM) before July 2022 (LG Chem pipeline, July 2022)
- 27 Mar 2019 LG Chem completes a phase II trial in Pneumococcal infections (Prevention, In infants) in South Korea (IM) (NCT03467984)
- 20 Mar 2018 LG Chem plans a phase II trial for Pneumococcal infections (Prevention), in April 2018 (NCT03467984)